Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 16 AL 30

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, Ereshefsky L, Olsson T, Ye N, Rosen L, Russell M, Maltby J, Eketjäll S, Kugler AR.

J Alzheimers Dis. 2017;55(3):1039-1053. doi: 10.3233/JAD-160701.

Phytochemicals in the Treatment of Alzheimer's Disease: A Systematic Review

D'Onofrio G, Sancarlo D, Ruan Q, Yu Z, Panza F, Daniele A, Greco A, Seripa D.

Curr Drug Targets. 2017;18(13):1487-1498. doi: 10.2174/1389450117666161102121553.

Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update

Habtemariam S.

Mini Rev Med Chem. 2017;17(8):667-674. doi: 10.2174/1389557516666161130100947.

Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue

Gauthier S.

Expert Rev Neurother. 2017 Jan;17(1):1-2. doi: 10.1080/14737175.2017.1268054.

Serotonin 5-HT(6) Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status

Ferrero H, Solas M, Francis PT, Ramirez MJ.

CNS Drugs. 2017 Jan;31(1):19-32. doi: 10.1007/s40263-016-0399-3.

NSAIDs Induced Regulation of Alternatively Spliced Transcript Isoforms: Possible Role in Cancer and Alzheimer Disease

Husain MA, Ur Rehman S, Sarwar T, Ishqi HM, Tabish M.

Curr Cancer Drug Targets. 2017;17(5):467-478. doi: 10.2174/1568009616666161216093403.

Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease

Ashok BS, Ajith TA, Sivanesan S.

Clin Exp Pharmacol Physiol. 2017 Mar;44(3):327-334. doi: 10.1111/1440-1681.12717.

Targeted Nanoparticles for the Treatment of Alzheimer's Disease

Martín-Rapun R, De Matteis L, Ambrosone A, Garcia-Embid S, Gutierrez L, de la Fuente JM.

Curr Pharm Des. 2017;23(13):1927-1952. doi: 10.2174/1381612822666161226151011.

Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy

Finke JM, Banks WA.

Hum Antibodies. 2017;25(3-4):131-146. doi: 10.3233/HAB-160306.

The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study

Gareri P, Castagna A, Cotroneo AM, Putignano D, Conforti R, Santamaria F, Marino S, Putignano S.

J Alzheimers Dis. 2017;56(2):557-565. doi: 10.3233/JAD-160808.

Editorial: Multitarget Molecules for Alzheimer's Disease Therapy

Marco-Contelles J, Fall Y.

Curr Top Med Chem. 2017;17(31):3318. doi: 10.2174/156802661731180221110409.

Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer's Disease

Goyal D, Shuaib S, Mann S, Goyal B.

ACS Comb Sci. 2017 Feb 13;19(2):55-80. doi: 10.1021/acscombsci.6b00116. Epub 2017 Jan 18.

Elucidating Treatment of Alzheimer's Disease via Different Receptors

Ul Islam B, Khan MS, Jabir NR, Kamal MA, Tabrez S.

Curr Top Med Chem. 2017;17(12):1400-1407. doi: 10.2174/1568026617666170103163715.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias